Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Phase 2 Completed 25 enrolled SCRI Development Innovations, LLC Sanofi · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study of the combination of oxaliplatin and trastuzumab as first or second line therapy in patients with stage IV, metastatic breast cancer

Timeline

Start: 2006-02
Primary completion: 2008-10
Completion: 2010-10

Publications

Results Yardley DA, Daniel D, Stipanov M, Drosick DR, Mainwaring M, Peyton J, Shastry M, Hainsworth JD. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer. Cancer Invest. 2010 Oct;28(8):865-71. doi: 10.3109/07357901003631031.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	Trastuzumab	Monoclonal antibody	6 mg/kg	Intravenous

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Summary

Timeline

Publications

Drugs

Indications